Health officials flag increased use of antivirals as COVID becomes endemic The new oral treatments are likely to play a more central role in limiting the impact of COVID-19, but health authorities are still assessing how that will take shape.
COVID antiviral order doubled ahead of PBS listing Paxlovid will be available on the Pharmaceutical Benefits Scheme from May, with ‘really positive responses’ reported so far.
Push for more detail on COVID-19 oral antivirals impact Experts highlight ‘crucial’ need for more understanding about how newly released oral antiviral drugs are performing in the broader population.
What GPs need to know about the new COVID antivirals Both oral antiviral COVID-19 treatments are now available, with significant restrictions, on the PBS.
COVID-19 antiviral pills to be reserved primarily for the unvaccinated Despite TGA approval last month, the two new COVID-19 treatments developed by Pfizer and Merck will not be widely available for prescription in the short-term.